Nan Fung Life Sciences
Nan Fung Life Sciences is a Series A to Series C stage investment firm. It has made 12 investments. 61% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $61.1M (across 17 rounds with reported amounts).
Portfolio
12
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
PB
Peter Bisgaard
Managing Director
CC
Charlotte Chow
Senior Associate
MG
Meng Gao
Chief Investment Officer
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
18 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Fountain Therapeutics | Series A | $15M | Nov 2021 |
| Fountain Therapeutics | Unknown | $6M | Jun 2021 |
 Encodia | Series C | $75M | Jan 2021 |
| EEngrail | Series A | $32M | Jan 2020 |
 SomaLogic | Series A | $121M | Jan 2020 |
| OOncologie | Series B | $80M | Jun 2019 |
 Eargo | Series D | $52M | Mar 2019 |
| OOncologie | Series B | $80M | Jan 2019 |
 Galera | Series C | — | Sep 2018 |
 Galera Therapeutics | Series C | $150M | Sep 2018 |
 Omniome | Series B | $60M | Jul 2018 |
| Omniome | Series B | $60M | Jan 2018 |
 Aptinyx Inc | Series B | $70M | Dec 2017 |
| Aptinyx Inc | Series B | $70M | Jan 2017 |
| Eargo | Series C | $45M | — |
| OOncologie | Seed | $16.5M | — |
| AAblaze | Series A | $75M | — |
 Engrail Therapeutics | Series A | $32M | — |
Top Co-Investors
Pivotal Life Sciences5 shared
Adage Capital Management4 shared
New Enterprise Associates4 shared
Rock Springs Capital4 shared
HBM Healthcare Investments4 shared
Novartis Venture Fund3 shared
Decheng Capital3 shared
ARCH Venture Partners3 shared
Biomatics Capital3 shared
Korea Investment Partners3 shared
Tekla Capital Management2 shared
Sofinnova Partners2 shared
Correlation Ventures2 shared
Stanford's StartX Fund2 shared
Maveron2 shared
DCVC2 shared
Domain Associates2 shared
Altitude Life Science Ventures2 shared
Hillhouse Investment2 shared
Alexandria Venture Investments2 shared
Last updated: 7 October 2026